In The Cancer Genome Atlas study of 117 early-stage, resected thymic tumor specimens, molecular hallmarks of thymomas, which accounted for the majority of cases of this study, also included GTF2I mutations, specific for type A, and mutations in HRAS and NRAS mutations. This evidence concerns the gene GTF2I and thymus neoplasm.